Listen
OCREVUS (ocrelizumab) - Multiple sclerosis
Reason for request
Summary of opinion
Favourable opinion for reimbursement in:
- the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
- the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
No clinical added value of the new solution for injection for subcutaneous administration form compared to the OCREVUS 300 mg concentrate for solution for infusion form (ocrelizumab)
already available.
Clinical Benefit
| Substantial |
The clinical benefit of OCREVUS 920 mg solution for injection for subcutaneous administration is substantial in the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
|
| Moderate |
The clinical benefit of OCREVUS 920 mg solution for injection for subcutaneous administration is moderate in the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
|
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the OCREVUS 300 mg concentrate for solution for infusion form already listed. |
